Received: 3 June 2021
Accepted: 25 February 2022
First Online: 24 March 2022
: This study was conducted with approval from Ethics Committee (Approval Number: B190300015). Written informed consent to participate and publish the material was obtained from all patients included in the study.
: In consideration of Cost Effectiveness and Resource Allocation reviewing and editing our submission, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to Cost Effectiveness and Resource Allocation and represent that they own all rights in the material submitted.
: K. Harigane: none declared. Y. Mochida: grant/research support from Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Teijin Limited, Chugai Pharmaceutical Co., Ltd, Zimmer-Biomet G.K., Asahi Kasei Pharma Co., and Eisai Co. T. Shimazaki: none declared. N. Kobayashi: none declared. Y. Inaba: none declared.